Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. - Insights
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and...
Urinary Steroid Profile [Test in Focus] - Insights
Irina Bancos, M.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken...
Paul Jannetto, Ph.D., explains the advantages that Mayo Clinic Laboratories' oral fluid drug screening offers over typical urine tests. Oral samples are easier to collect and harder to adulterate.
Learn why liquid biopsy testing is a viable alternative to tissue-based biopsy testing for certain patients with cancer.
Histiocytic neoplasms - Insights
Learn more about how Mayo Clinic Laboratories’ next-generation sequencing panel for histiocytic neoplasms can help physicians accurately diagnose patients and guide treatment for their patients.
Rapid hereditary breast cancer - Insights
Learn how our rapid breast cancer treatment panel delivers results in 10 to 14 days and detects 11 genes linked to lifetime breast cancer risk.
Chronic lymphocytic leukemia - Insights
Learn how we increase the quality of care by performing all of our chronic lymphocytic leukemia testing at a single facility.
Lung Cancer Testing - Mayo Clinic Laboratories
Mayo Clinic Laboratories innovates at the speed of medical advancement, and offers comprehensive options for diagnostic, prognostic, and predictive lung cancer testing.
Learn about our hereditary cancer test offerings, including single-gene assays that evaluate specific genes already identified in a parent.
Learn how reliable laboratory diagnosis of a platelet disorders can impact patients’ and their family members' clinical management and outcomes.